- AbbVie announced that Canada’s Drug Agency (CDA-AMC) has recommended Ubrelvy (ubrogepant) for reimbursement with conditions for the acute treatment of migraine, with or without aura, in adults experiencing moderate-to-severe migraine attacks.
- The recommendation is backed by data from the pivotal Phase III ACHIEVE I and ACHIEVE II trials, where Ubrelvy demonstrated efficacy in achieving pain freedom, pain relief, and resolution of the most bothersome migraine-associated symptoms.
- The review incorporated feedback from Canadian clinicians and patient organizations, including Migraine Canada, Migraine Québec, and the Canadian Migraine Society, recognizing the need for more migraine-specific acute treatment options for the nearly 5 million Canadians living with migraine.
- AbbVie noted that the positive recommendation is an important step toward improving public access to personalized migraine care and will now support discussions with governments and healthcare partners to advance reimbursement across Canada.
Takeaways:
If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for an oral gepant in a market where patients and clinicians have been asking for more personalized acute options. That matters because migraine care is underpenetrated and often poorly controlled, so reimbursement could shift prescribing toward newer branded therapies, improve treatment access for moderate-to-severe attacks, and give AbbVie a better position in a category.
Source: CA Newswire
